GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
85 articles in GLP-1 & Metabolic · page 6 of 8
The Incretin Effect, Explained
Why oral glucose triggers far more insulin than the same glucose given intravenously, and what happens to that signal in type 2 diabetes.
Read →GLP-1s and Pancreatitis: What the Data Says
A long-standing concern examined against pooled trial meta-analyses. The signal, if real, looks small.
Read →GLP-1s and Gastroparesis: Weighing the Risk
Slowed stomach emptying is both the mechanism and the side effect. What the cohort data and anesthesia guidance show.
Read →GLP-1 Dosing and Titration: Why Slow Wins
Wegovy escalates over 16+ weeks for a reason: slow titration trades a slower ramp for far better tolerability.
Read →GLP-1s and Thyroid Cancer: Reading the Black-Box Warning
A 437,000-person BMJ cohort found no clear thyroid-cancer signal. The warning rests on rodent data, not human harm.
Read →GLP-1s and Kidney Outcomes: The FLOW Trial, Explained
FLOW cut serious kidney events by 24% in diabetics with chronic kidney disease. What it shows and doesn't.
Read →How GLP-1, GIP, and Glucagon Differ
Three hormones, three roles — the logic behind single, dual, and triple agonist drugs.
Read →GLP-1s and PCOS: What the Research Shows
A 2026 meta-analysis of 11 trials found modest BMI gains but low-certainty evidence on PCOS hormones and cycles.
Read →GLP-1 Receptor Agonists in the Brain: Appetite and Beyond
These drugs act centrally, not just in the gut. What that means for appetite, reward, and side effects.
Read →GLP-1s and Alcohol Use: An Emerging Signal
Anecdotes and early data hint at reduced drinking. A measured look at a genuinely interesting signal.
Read →GLP-1s and Cardiovascular Outcomes Beyond SELECT
SELECT was the landmark, but the cardiovascular story is broader. What the wider trial evidence shows.
Read →Compounded Semaglutide: The Risks and Realities
FDA found patients drew 5–20x the intended dose of compounded semaglutide. What to understand about the market.
Read →